Inflammation and Multiple Sclerosis: a Close Interplay
In the first century A.D., Cornelius Celsus first described the inflammatory process by indicating its five cardinal signs: rubor, tumor, color, dolor and functio laesa. The intrinsic characteristics of the inflammatory process were subsequently described in 1793 by John Hunter who stated that the inflammatory reaction is not a disease but a specific response that has a “salutary” effect on its host. The pathological aspects of the inflammatory process were first described in the nineteenth century by Julius Cohnheim who claimed that in the inflammed tissue there is an initial vasodilatation associated with increased vascular permeability and changes in the blood flow causing edema and leukocyte extravasation. At the end of the nineteenth century, Elia Metchnikoff suggested that the purpose of the inflammatory process is to bring phagocytic cells to the injured areas to engulf invading bacteria. At the beginning of the twentieth century, Paul Enrich indicated that inflammation involves not only cellular (phagocytosis) but also serum factors (antibodies), and Sir Thomas Lewis concluded that the vascular changes occurring during the inflammatory process are mainly mediated by chemical substances (reviewed in ).
KeywordsMultiple Sclerosis Multiple Sclerosis Patient Myelin Basic Protein Experimental Allergic Encephalomyelitis Phorbol Myristate Acetate
Unable to display preview. Download preview PDF.
- 1.Cotran RS, Kumar V, Robbins SL (1994) Pathologic basis of disease. WB Saunders, PhiladelphiaGoogle Scholar
- 7.Chomarat P, Banchereau J (1997) An update on interleukin-4 and its receptor. Eur Cytok Net 8: 333–344Google Scholar
- 14.Esiri MM, Gay D (1997) The immunocytochemistry of multiple sclerosis plaques. In: Raine CS, McFarland HF, Tourtellotte WW (eds) Multiple sclerosis. Clinical and pathogenetic basis. Chapman & Hall, London, pp 173–186Google Scholar
- 20.Cuzner ML, Gveric D, Strand C et al. (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55:1194–1204PubMedCrossRefGoogle Scholar
- 36.Mein LE, Hoch RM, Dornmair K et al. (1997) Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. Am J Pathol 150: 445–453Google Scholar